Atp7A is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| ATPase 7A |
|---|
| Gene Symbol | ATP7A |
| Full Name | ATPase 7A (Copper Transporting ATPase) |
| Chromosome | Xq21.1 |
| NCBI Gene ID | 538 |
| OMIM | 300011 |
| Ensembl ID | ENSG00000136939 |
| UniProt ID | Q9Y5K9 |
| Protein Length | 1500 amino acids |
| Molecular Weight | 163 kDa |
| Associated Diseases | Menkes Disease, Occipital Horn Syndrome, Alzheimer's Disease |
ATP7A (ATPase 7A) encodes a P-type copper-transporting ATPase that is essential for systemic copper homeostasis. This transmembrane protein is responsible for copper absorption from the intestine, distribution to peripheral tissues, and incorporation into copper-dependent enzymes. ATP7A is expressed in most tissues except the liver, making it the primary copper transporter for extrahepatic copper metabolism.
Mutations in ATP7A cause Menkes disease, a severe X-linked recessive disorder characterized by progressive neurodegeneration, connective tissue abnormalities, and early death if untreated. The disease results from impaired copper absorption and distribution, leading to severe copper deficiency in the brain and other tissues. Interestingly, emerging research suggests ATP7A dysfunction may also play a role in Alzheimer's disease and other neurodegenerative conditions.
ATP7A is a large transmembrane protein of 1500 amino acids with a molecular weight of approximately 163 kDa. Like ATP7B, it belongs to the P-type ATPase family and contains similar structural domains:
¶ Transmembrane Domain
- 8 Transmembrane Helices: Form the copper translocation pore
- Copper Binding Sites: 6 N-terminal CXXC motifs for copper binding
- Gate Region: Regulates access to the transport channel
¶ Functional Domains
- N-terminal Metal-Binding Domain: Contains multiple copper-binding motifs
- Phosphorylation Domain: Conserved DKTGTLT motif
- Actuator Domain: Facilitates conformational changes
- ATP-binding Domain: Catalyzes ATP hydrolysis
ATP7A operates through a similar mechanism to ATP7B:
- Copper Binding: Copper ions bind to N-terminal metal-binding sites
- ATP Hydrolysis: Energy from ATP drives conformational changes
- Translocation: Copper is transported across the membrane
- Release: Copper is released into the extracellular space or incorporated into enzymes
- Reset: Return to original conformation
- Intestinal Absorption: Primary transporter for dietary copper uptake
- Systemic Distribution: Delivers copper to peripheral tissues
- Enzyme Maturation: Supplies copper to Cu/ZN superoxide dismutase, cytochrome c oxidase
- Blood-Brain Barrier Transport: Essential for copper entry into the brain
ATP7A is widely expressed with highest levels in:
- Intestinal Epithelium: Small intestine enterocytes
- Placenta: Trophoblast cells
- Brain: Neurons, endothelial cells of BBB
- Kidney: Tubular cells
- Heart: Cardiomyocytes
- Lung: Alveolar epithelium
ATP7A localizes to:
- Plasma Membrane: Basolateral membrane of intestinal cells
- Trans-Golgi Network: For enzyme copper delivery
- Endosomes: Mobile pool for copper distribution
Menkes disease results from ATP7A deficiency:
- Neurological Features: Severe developmental delay, hypotonia, seizures
- Connective Tissue: Hyperextensible skin, joint hypermobility, vascular tortuosity
- Hair Abnormalities: Kinky, brittle hair (pili torti)
- Failure to Thrive: Growth retardation
- Early Mortality: Usually within early childhood without treatment
The neuropathology includes:
- Cerebellar atrophy
- White matter abnormalities
- Neuronal loss
- Dendritic abnormalities
A milder allelic variant:
- Skeletal abnormalities (occipital horns)
- Mild neurological involvement
- Longer survival
ATP7A implications in AD:
- Copper Homeostasis: Altered in AD brain
- Amyloid Processing: Affects Aβ generation and aggregation
- Oxidative Stress: Modulates ROS production
- Blood-Brain Barrier: Affects copper entry to brain
- Parkinson's Disease: Altered neuronal copper handling
- Amyotrophic Lateral Sclerosis: Copper metabolism in motor neurons
- Prion Disease: Copper-binding in prion protein metabolism
Current therapies include:
- Copper Histidine: Subcutaneous copper supplementation
- Early Intervention: Critical for neurological outcomes
- Gene Therapy: Experimental AAV-mediated delivery
ATP7A-targeted approaches:
- Copper Delivery: Enhancing brain copper levels
- Gene Therapy: Restoring ATP7A function
- Protein Modulators: Pharmacological chaperones
- BBB-Penetrant Copper Compounds: Targeted delivery
Pharmaceutical strategies:
- Copper Ionophores: Facilitate copper entry into cells
- ATP7A Expression Modulators: Increase protein levels
- Protein Stabilizers: Rescue mutant protein function
Atp7a knockout mice:
- Embryonic lethality (most die in utero)
- Phenocopy Menkes disease
- Copper deficiency in brain
Tissue-specific knockouts reveal:
- Neuronal knockout: Neurodegeneration
- Intestinal knockout: Systemic copper deficiency
- Brain-specific: Cognitive deficits
ATP7A-related biomarkers:
- Serum Copper: Decreased in Menkes disease
- Ceruloplasmin: Reduced activity
- Hair Copper: Low levels
- CSF Copper: May be altered in neurodegeneration
ATP7A interacts with:
- Metal Metabolism: Central copper homeostasis
- Mitochondrial Function: Cytochrome c oxidase maturation
- Oxidative Stress Response: SOD1 activation
- BBB Integrity: Endothelial copper transport
- Neuroinflammation: Copper's immunomodulatory effects
The study of Atp7A has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
1. Lutsenko S, et al. (2007). "Function and regulation of human copper-transporting ATPases." Physiological Reviews. 87(3):1011-1046.
2. Vulpe C, et al. (1993). "Isolation of a candidate gene for Menkes disease." Nature Genetics. 3(1):7-13.
3. Kodama H, et al. (2019). "Menkes disease: pathophysiology and therapy." Brain Development. 41(8):615-623.
4. Nobuta H, et al. (2019). "ATP7A trafficking and Cu supplementation in neurons." Journal of Neurochemistry. 151(2):139-151.
5. White C, et al. (2020). "Copper homeostasis in the brain and Alzheimer's disease." Journal of Alzheimer's Disease. 73(3):823-834.
6. Davies KM, et al. (2013). "Copper pathology in neurodegenerative diseases." Acta Neuropathologica Communications. 1(1):81.
7. Bertini I, Rosato A (2008). "Menkes disease." Cell and Tissue Research. 332(3):331-340.
8. Kaler SG (2011). "ATP7A-related copper transport diseases." Handbook of Clinical Neurology. 105:343-366.